This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
by Zacks Equity Research
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.
FOLDPositive Net Change RCKTPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs earnings
Novavax to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA to remove the clinical hold on its two vaccine programs.
SNYPositive Net Change NVAXPositive Net Change WVEPositive Net Change LEGNNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
NVSPositive Net Change LLYPositive Net Change NKTRPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
NVSPositive Net Change BIIBPositive Net Change ALLOPositive Net Change IMVTPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
by Zacks Equity Research
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance. Stock rallies.
FOLDPositive Net Change PBYIPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs earnings
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
BIIBPositive Net Change FOLDPositive Net Change ALLOPositive Net Change CSTLPositive Net Change
biotechs earnings medical
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
by Zacks Equity Research
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
BIIBPositive Net Change FOLDPositive Net Change IOVAPositive Net Change CSTLPositive Net Change
biotechs earnings medical pharmaceuticals
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
by Zacks Equity Research
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
SNYPositive Net Change BIIBPositive Net Change FOLDPositive Net Change DNLIPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
REGNPositive Net Change FOLDPositive Net Change NTLAPositive Net Change CSTLPositive Net Change
biotechs earnings
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bull run. Some of the stocks seeing price strength are CDXC, SEZL, TILE, BGC, CORT.
BGCNegative Net Change CORTNegative Net Change TILENegative Net Change SEZLPositive Net Change
biotechs business-services consumer-discretionary finance medical
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
by Zacks Equity Research
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.
BIIBPositive Net Change MRKPositive Net Change MRNAPositive Net Change FOLDPositive Net Change
biotechs medical messenger-rna pharmaceuticals
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.
GSKPositive Net Change GILDNegative Net Change EXELNegative Net Change FOLDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
by Zacks Equity Research
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.
TEVAPositive Net Change FOLDPositive Net Change CRSPPositive Net Change LSTANegative Net Change
biotechs earnings
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.
NVSPositive Net Change BIIBPositive Net Change CPRXPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
NVSPositive Net Change BIIBPositive Net Change PCRXNegative Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
NVSPositive Net Change BIIBPositive Net Change ACADPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
by Zacks Equity Research
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
BIIBPositive Net Change FOLDPositive Net Change SRPTPositive Net Change
biotechs earnings gene-therapy medical pharmaceuticals
Markets Tear Off the Lid in Hump-Day Trading
by Mark Vickery
A decisive win for Donald Trump and the Republican Party in both the White House and Congress will likely usher in very aggressive pro-business policies.
QCOMNegative Net Change GILDNegative Net Change ELFNegative Net Change
biotechs consumer-discretionary earnings semiconductor
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
by Zacks Equity Research
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
NVSPositive Net Change NVOPositive Net Change LLYPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.
BEAMPositive Net Change FOLDPositive Net Change CRSPPositive Net Change AVIRPositive Net Change
biotechs earnings
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
by Zacks Equity Research
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.
FOLDPositive Net Change CRSPPositive Net Change AVIRPositive Net Change APLSPositive Net Change
biotechs earnings
Pre-Markets Soar after Trump Wins U.S. Presidential Election
by Zacks Equity Research
Pre-Markets Soar after Trump Wins U.S. Presidential Election
QCOMNegative Net Change TMPositive Net Change GILDNegative Net Change TSLANegative Net Change TRIPNegative Net Change ACBNegative Net Change COINNegative Net Change ARKBNegative Net Change
auto-tires-trucks biotechs bitcoin blockchain cannabis cryptocurrency etfs semiconductor
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
by Zacks Equity Research
RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.
REGNPositive Net Change NVSPositive Net Change RAREPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
BIIBPositive Net Change VRTXPositive Net Change FOLDPositive Net Change CRSPPositive Net Change
biotechs cell-therapy crispr gene-therapy medical pharmaceuticals
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
by Kinjel Shah
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
NVOPositive Net Change TEVAPositive Net Change GILDNegative Net Change MRNAPositive Net Change VTRSNegative Net Change
biotechs pharmaceuticals